CloneID: E5
Antigen Long Description: The original antibody was generated by immunizing Lama glama with omalizumab conjugated with human serum albumin. The panning for selection of anti-omalizumab nanobodies involved a first step of pre-adsorption to remove reactive clones against epitopes other than the paratope of omalizumab. Phage supernatents were then incubated with omalizumab to isolate the original antibody.
Origin Pub PMID: 34931798
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This is a chimeric antibody, developed from the original camelid VHH antibody, specifically engineered for enhanced compatibility with existing reagents, assays, and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Specificity Statement: This antibody shows reactivity against omalizumab, which is a humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. It inhibits the binding of IgE to FcεRI on mast cells and basophils by binding to an antigenic epitope on IgE that overlaps with the site to which FcεRI binds. Omalizumab was designed to reduce sensitivity to allergens and is used for treating chronic idiopathic urticaria, and allergic asthma.
Application Notes (Clone): The binding characterization of this antibody was done using ELISA. This antibody in combination with an anti-aztreonam antibody AbAb-Aztreo and anti-ampicillin antibody D51 was used in the generation of a bispecific antibody for determination of allergy against these antibiotics (PMID: 34931798).
English
Deutsch
